Abstract
Immunoglobulin A nephropathy is the most common glomerulopathy throughout the world. Immunoglobulin A nephropathy is not continuously benign, and it should determine factors either clinical or morphological have prognostic significance. It is necessary to found which individuals are at risk of a disease evolution and to recommend the exact therapy to the patients. Several morphological, biological and clinical parameters have been defined and are presently applied to a better understanding of individuals at risk, to suggest the exact therapy and to monitor the treatment impact and the immunoglobulin A nephropathy evolution over time. In this regard, more attention to immunostaining data and investigating their possible prognostic significance suggests.